Haleon CEO: China and India are Key Markets

Haleon CEO Brian McNamara identified China and India as critical growth markets for the consumer health company’s expansion strategy during a March 2026 Bloomberg interview. The focus on Asia aligns with Haleon’s push to broaden its product portfolio in high-potential regions, prioritizing emerging economies over saturated Western markets. McNamara emphasized China’s scale and India’s rapid consumer demand as key drivers, signaling long-term investment in both countries’ healthcare sectors. The strategy reflects Haleon’s post-spinoff independence from GSK, aiming to leverage Asia’s rising middle class for revenue growth beyond traditional pharmaceuticals. No specific financial targets were disclosed, but the CEO framed the move as essential to sustaining global competitiveness amid shifting consumer health trends.